91ÖÆƬ³§

Published on Market Research Reports® Inc. ()

Home > Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2018

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2018

Publication ID: 
GMD0218044
Publication Date: 
February 20, 2018
Pages: 
131
Publisher: 
Global Markets Direct
Countries: 
Global [1]
USD 2,000.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Drug Pipeline [2]
Pharma & Healthcare [3]
Description: 

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2018, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 7, 5, 16 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 2, 1, 1 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents: 

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Influenza A Virus, H3N2 Subtype Infections - Overview 8
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 18
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Adimmune Corp 27
Aphios Corp 28
AusBio Ltd 28
BioCryst Pharmaceuticals Inc 28
BiondVax Pharmaceuticals Ltd 29
Cadila Healthcare Ltd 29
Celltrion Inc 30
Emergent BioSolutions Inc 31
FluGen Inc 31
Inovio Pharmaceuticals Inc 31
Jiangsu Kanion Pharmaceutical Co Ltd 32
Johnson & Johnson 33
Medicago Inc 33
MedImmune LLC 34
Mucosis BV (Inactive) 34
NanoViricides Inc 35
Novavax Inc 35
OPKO Health Inc 36
Sanofi 36
Sanofi Pasteur SA 37
Sarepta Therapeutics Inc 37
SK Chemicals Co Ltd 38
VBI Vaccines Inc 38
Influenza A Virus, H3N2 Subtype Infections - Drug Profiles 40
APP-0205 - Drug Profile 40
APP-309 - Drug Profile 41
Aspidasept - Drug Profile 42
AV-5075S - Drug Profile 43
AV-5080 - Drug Profile 44
C-05 - Drug Profile 45
cetylpyridinium chloride - Drug Profile 46
CTP-27 - Drug Profile 47
Fluad (quadrivalent) - Drug Profile 48
Gamma-Flu - Drug Profile 49
influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 50
influenza [strain A/H3N2] vaccine - Drug Profile 51
influenza [strain A/H3N2] vaccine - Drug Profile 52
influenza [strain A/H3N2] vaccine - Drug Profile 53
influenza [strain A/H3N2v] vaccine - Drug Profile 54
influenza [strain A/H3N2v] vaccine - Drug Profile 55
influenza [strain H3N2] vaccine - Drug Profile 56
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 57
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 58
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 60
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine - Drug Profile 61
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 62
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 63
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 66
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 67
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 68
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 69
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 70
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 71
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 72
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 73
influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile 74
influenza [strains A/H3N2 + A/H1N1] vaccine - Drug Profile 76
M-001 - Drug Profile 77
MD-2009 - Drug Profile 84
NBP-607 - Drug Profile 85
NEO-8877 - Drug Profile 87
NP-025 - Drug Profile 88
NSC-61610 - Drug Profile 89
NVINF-1 - Drug Profile 90
NVINF-2 - Drug Profile 95
Peptides for Influenza Infections - Drug Profile 98
peramivir - Drug Profile 99
pertussis [strain BPZE1] vaccine - Drug Profile 102
pimodivir hydrochloride - Drug Profile 104
PNSIA-28 - Drug Profile 107
PrEP-001 - Drug Profile 108
radavirsen - Drug Profile 110
REDEE FLU - Drug Profile 112
Small Molecules for RSV and Influenza A Infections - Drug Profile 114
Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections - Drug Profile 115
UV-4B - Drug Profile 116
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects 118
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products 120
Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones 121
Featured News & Press Releases 121
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables
List of Tables
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AusBio Ltd, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Cadila Healthcare Ltd, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Emergent BioSolutions Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune LLC, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis BV (Inactive), H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2018
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H1 2018

List of Figures
List of Figures
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Companies Mentioned: 

AbbVie Inc
Adimmune Corp
Aphios Corp
AusBio Ltd
BioCryst Pharmaceuticals Inc
BiondVax Pharmaceuticals Ltd
Cadila Healthcare Ltd
Celltrion Inc
Emergent BioSolutions Inc
FluGen Inc
Inovio Pharmaceuticals Inc
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Medicago Inc
MedImmune LLC
Mucosis BV (Inactive)
NanoViricides Inc
Novavax Inc
OPKO Health Inc
Sanofi
Sanofi Pasteur SA
Sarepta Therapeutics Inc
SK Chemicals Co Ltd
VBI Vaccines Inc

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ìý

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ìý

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/global-markets-direct/influenza-virus-h3n2-subtype-infections-pipeline-review-h1-2018

Links
[1] /countries/global[2] /drug-pipeline[3] /pharma-healthcare